|Systematic (IUPAC) name|
|Trade names||Macrobid, Macrodantin, others|
|Excretion||urine and bile|
|Melt. point||270–272 °C (518–522 °F) (decomp.)|
|(what is this?)|
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
Nitrofurantoin has been available for the treatment of urinary tract infections (UTIs) since 1953. Its current uses include the treatment of uncomplicated urinary tract infections and prophylaxis against urinary tract infections in people prone to recurrent UTIs. Increasing bacterial antibiotic resistance to other commonly used agents, such as fluoroquinolones and trimethoprim/sulfamethoxazole, has led to increased interest in using nitrofurantoin. Several trials comparing nitrofurantoin to other commonly used agents have shown that this drug results in similar cure rates for uncomplicated urinary tract infections. The efficacy of nitrofurantoin in treating urinary tract infections combined with a low rate of bacterial resistance to this agent makes it one of the first-line agents for treating uncomplicated urinary tract infections as recommended by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.
Treatment is for five to seven days. Shortened courses of 3 days are not recommended. Nitrofurantoin should be taken with food, as this improves the absorption and bioavailability of the drug as well as lessening the common side effects of nausea and vomiting.
Nitrofurantoin has been shown to have good activity against the following organisms:
- E. coli,
- Staph. saprophyticus,
- Coagulase negative staphylococci,
- Enterococcus faecalis,
- Staphylococcus aureus,
- Streptococcus agalactiae,
- Citrobacter species, and
- Klebsiella species,
and is used in the treatment of infections caused by these organisms.
Many or all strains of the following are resistant to nitrofurantoin:
Antibiotic susceptibility testing should always be performed to further elucidate the resistance profile of the particular strain of bacteria causing infection.
Nitrofurantoin is Pregnancy Category B. It is one of the few drugs that is commonly used in pregnancy to treat urinary tract infections. Other drugs used for urinary tract infections in pregnancy include cephalexin, amoxicillin, and pivmecillinam. The drug should not be given to women in late pregnancy due to the potential risk of hemolytic anemia in the newborn, as the newborn has not yet developed the enzymatic pathways necessary for glutathione metabolism and the drug may cause oxidative damage to the red blood cells. It has been shown that newborns of women given this drug late in pregnancy had a higher risk of developing neonatal jaundice.
Several trials on the safety and teratogenicity of nitrofurantoin in pregnancy have shown mixed results. A retrospective study in 2009 claimed that several birth defects, such as hypoplastic left heart syndrome, ophthalmic malformations, cleft lip and cleft palate, and atrial septal defect were more common in neonates exposed to nitrofurantoin during pregnancy. A meta analysis of four out of twenty-two available studies on the safety of nitrofurantoin found no increased risk. A case-control study in 1998 found an increased risk of craniosynostosis after exposure to "nitrosatable" drugs. A more recent 2013 population-based cohort study which used women registered in the Norwegian Prescription Database and linked the subjects to a birth outcomes database, however, found no increased risk of major malformations in neonates born to women who took nitrofurantoin in early pregnancy. Many of the studies showing increased risk of nitrofurantoin had limitations and relied on patients' recall of the antibiotics they took during pregnancy rather than objective data, which may have led to recall bias. Nevertheless, in light of this conflicting data, the American College of Obstetrics and Gynecology (ACOG) recommends using antibiotics only for appropriate indications and for the shortest effective duration.
Organisms are said to be susceptible to nitrofurantoin if their minimum inhibitory concentration (MIC) is 32 μg/mL or less. The peak blood concentration of nitrofurantoin following an oral dose of nitrofurantoin 100 mg, is less than 1 μg/mL and may be undetectable; The bioavailability is about 90% and the urinary excretion is 40% tissue penetration is negligible; the drug is well concentrated in the urine: 75% of the dose is rapidly metabolised by the liver, but 25% of the dose is excreted in the urine unchanged, reliably achieving levels of 200 μg/ml or more. For this reason, nitrofurantoin cannot be used to treat anything other than simple cystitis.
At the concentrations achieved in urine (>100 microgm/mL), nitrofurantoin is bacteriocidal. It is bacteriostatic against most susceptible organisms at concentrations less than 32 micrograms per milliliter.
Resistance to nitrofurantoin may be chromosomal or plasmid mediated and involves inhibition of nitrofuran reductase. Acquired resistance in E. coli continues to be rare.
Nitrofurantoin and its metabolites are excreted mainly by the kidneys. In renal impairment, the concentration achieved in urine may be subtherapeutic. Nitrofurantoin should not be used in patients with a creatinine clearance of 60 mL/min or less. However a retrospective chart review may suggest that nitrofurantoin is not contraindicated in this population.
The mechanism of action of nitrofurantoin is unique and complex. The drug works by damaging bacterial DNA, since its reduced form is highly reactive. This is made possible by the rapid reduction of nitrofurantoin inside the bacterial cell by flavoproteins (nitrofuran reductase) to multiple reactive intermediates that attack ribosomal proteins, DNA, respiration, pyruvate metabolism and other macromolecules within the cell. Nitrofurantoin exerts greater effects on bacterial cells than mammalian cells because bacterial cells activate the drug more rapidly. It is not known which of the actions of nitrofurantoin is primarily responsible for its bactericidal activity. It is likely that the broad mechanism of action for this drug is responsible for the low development of resistance to its effects, as the drug affects many different processes important to the bacterial cell.
The most common side effects with nitrofurantoin are nausea, headache, and flatulence. Less common adverse events (occurring in less than 1% of those taking the drug) include:
- Gastrointestinal: Diarrhea, dyspepsia, abdominal pain, constipation, emesis
- Neurologic: Dizziness, drowsiness, amblyopia
- Respiratory: Acute pulmonary hypersensitivity reaction
- Allergic: Pruritus, urticaria
- Dermatologic: Alopecia
- Miscellaneous: Fever, chills, malaise
Patients should be informed that nitrofurantoin colours urine brown; this is completely harmless.
Some of the more serious but rare side effects of nitrofurantoin have been a cause of concern. These include pulmonary reactions, hepatotoxicity, and neuropathy.
The pulmonary toxicity caused by nitrofurantoin can be categorized into acute, subacute, and chronic pulmonary reactions. The acute and subacute reactions are thought to be due to a hypersensitivity reaction and often resolve when the drug is discontinued. Acute reactions occur in about 1/5000 women who take the drug and are independent of dose. These reactions usually develop 3–8 days after the first dose of nitrofurantoin, but may occur from a few hours to a few weeks after starting the drug. Symptoms include fever, dyspnea, chills, cough, pleuritic chest pain, headache, back pain, and epigastric pain. Chest radiograph will often show unilateral or bilateral infiltrates similar to pulmonary edema. Treatment includes discontinuation of the nitrofurantoin, which should result in symptom improvement within 24 hours.
Chronic pulmonary reactions caused by nitrofurantoin include diffuse interstitial pneumonitis, pulmonary fibrosis, or both. This uncommon reaction may occur 1 month to 6 years after starting the drug and is usually related to the total lifetime dose of nitrofurantoin. This reaction manifests with progressive shortness of breath. It is important to recognize nitrofurantoin as possible cause of symptoms and discontinue the drug when the suspicion of pulmonary side effects arises.
Hepatic reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely. The onset of chronic active hepatitis may be insidious, and patients should be monitored periodically for changes in biochemical tests that would indicate liver injury. These reactions usually occur after exposure to the drug for more than 6 weeks. If signs of liver failure are observed in a patient taking nitrofurantoin, the drug should be discontinued. Re-challenge with the drug at a later date is not recommended, as the reaction may have a hypersensitivity component and recur when the drug is resumed.
Neuropathy is a rare side effect of taking nitrofurantoin. Patients may experience numbness and tingling in a stocking-glove pattern, which may or may not improve upon discontinuation of the drug.
Nitrofurantoin is contraindicated in patients with decreased renal function (CrCl < 60mL/min) due to systemic accumulation and subtherapeutic levels reached in the urinary tract. However, a retrospective chart review suggests that the data for this cutoff is slim and that a cutoff of CrCl < 40mL/min would be more appropriate. Many of the severe side effects of this drug are more common in the elderly and those with renal impairment, as this causes the drug to be retained in the body and reach higher systemic levels. Thus, the drug is not recommended for the elderly population according to 2012 AGS Beers Criteria.
Nitrofurantoin is also contraindicated in neonates (babies up to the age of one month), as they have immature enzyme systems in their red blood cells (glutathione instability) and nitrofurantoin must therefore not be used because it can cause haemolytic anaemia. For the same reason, nitrofurantoin should not be given to pregnant women after 38 weeks of pregnancy, or who are about to give birth. Nitrofurantoin is contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency because of risk of intravascular hemolysis resulting in anemia.
Use in animal feed
Residues from the breakdown of nitrofuran veterinary antibiotics, including nitrofurantoin, have been found in chicken in Vietnam, China, Brazil, and Thailand. The European Union banned the use of nitrofurans in food producing animals by classifying it in ANNEX IV (list of pharmacologically active substances for which no maximum residue limits can be fixed) of the Council Regulation 2377/90. The Food and Drug Administration (FDA) of the United States has prohibited furaltadone since February 1985 and withdrew the approval for the other nitrofuran drugs (except some topical uses) in January 1992. The topical use of furazolidone and nitrofurazone was prohibited in 2002. Australia prohibited the use of nitrofurans in food production in 1992. Japan did not allocate MRLs for nitrofurans leading to the implementation of a "zero tolerance or no residue standard". In Thailand, the Ministry of Health issued in 2001 Proclamation No. 231 MRL of veterinary drug in food which did not allocate MRL for nitrofurans. The Ministry of Agriculture and Cooperatives had already prohibited importation and use of furazolidone and nitrofurazone in animal feed in 1999 which was extended to all nitrofurans in 2002. Several metabolites of nitrofurans, such as furazolidone, furaltadone and nitrofurazone cause cancer or genetic damage in rats.
Nitrofurantoin should be taken with food to improve its absorption.
- Furadantin (U.S., UK)
- Macrobid (long acting preparation for twice daily dosing available in U.S., Canada, and UK)
- Macrodantin (U.S., UK, Israel)
- Uro-Tablinen, Furadantin, Nifuretten, Nifurantin, Urodin (GER, A, CH)
- Macrodantina (Mexico)
- Furatin, Niftran(by Ranbaxy), Niftas(by Intas Pharmaceuticals) (India)
- Uvamin (Middle East)
- Parrott, E. L.; Matheson Jr, L. E. (1977). "Rectal absorption of nitrofurantoin". Journal of Pharmaceutical Sciences 66 (7): 955–958. doi:10.1002/jps.2600660713. PMID 886458.
- "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.
- "Macrobid Drug Label". FDA. Retrieved 21 April 2014.
- Garau J (January 2008). "Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline". Clin. Microbiol. Infect. 14 Suppl 1: 198–202. doi:10.1111/j.1469-0691.2007.01852.x. PMID 18154548.
- McKinnell, JA; Stollenwerk, NS; Jung, CW; Miller, LG (Jun 2011). "Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.". Mayo Clinic proceedings 86 (6): 480–8. doi:10.4065/mcp.2010.0800. PMC 3104907. PMID 21576512.
- Christiaens, TC; De Meyere, M; Verschraegen, G; Peersman, W; Heytens, S; De Maeseneer, JM (Sep 2002). "Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women.". The British journal of general practice : the journal of the Royal College of General Practitioners 52 (482): 729–34. PMC 1314413. PMID 12236276.
- Gupta, K; Hooton, TM; Roberts, PL; Stamm, WE (Nov 12, 2007). "Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women.". Archives of Internal Medicine 167 (20): 2207–12. doi:10.1001/archinte.167.20.2207. PMID 17998493.
- Iravani, A; Klimberg, I; Briefer, C; Munera, C; Kowalsky, SF; Echols, RM (Mar 1999). "A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.". The Journal of antimicrobial chemotherapy. 43 Suppl A: 67–75. doi:10.1093/jac/43.suppl_1.67. PMID 10225575.
- Stein, GE (Nov 1999). "Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection.". Clinical therapeutics 21 (11): 1864–72. doi:10.1016/S0149-2918(00)86734-X. PMID 10890258.
- Gupta, K.; Hooton, T. M.; Naber, K. G.; Wullt, B.; Colgan, R.; Miller, L. G.; Moran, G. J.; Nicolle, L. E.; Raz, R.; Schaeffer, A. J.; Soper, D. E. (2011). "International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clinical Infectious Diseases 52 (5): e103–e120. doi:10.1093/cid/ciq257. PMID 21292654.
- Lipsky, Benjamin A.; Byren, Ivor; Hoey, Christopher T. "Treatment of Bacterial Prostatitis". Clinical Infectious Diseases 50 (12): 1641–1652. doi:10.1086/652861.
- Solomkin, Joseph S.; Mazuski, John E.; Bradley, John S.; Rodvold, Keith A.; Goldstein, Ellie J. C.; Baron, Ellen J.; O’Neill, Patrick J.; Chow, Anthony W.; Dellinger, E. Patchen; Eachempati, Soumitra R.; Gorbach, Sherwood; Hilfiker, Mary; May, Addison K.; Nathens, Avery B.; Sawyer, Robert G.; Bartlett, John G. "Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Clinical Infectious Diseases 50 (2): 133–164. doi:10.1086/649554. PMID 20034345.
- Gleckman, R; Alvarez, S; Joubert, DW (Mar 1979). "Drug therapy reviews: nitrofurantoin.". American journal of hospital pharmacy 36 (3): 342–51. PMID 369367.
- Gupta, K; Scholes, D; Stamm, WE (Feb 24, 1999). "Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women.". JAMA: the Journal of the American Medical Association 281 (8): 736–8. doi:10.1001/jama.281.8.736. PMID 10052444.
- Lee M, Bozzo P, Einarson A, Koren G (June 2008). "Urinary tract infections in pregnancy". Can Fam Physician 54 (6): 853–4. PMC 2426978. PMID 18556490.
- Nordeng, H; Lupattelli, A; Romøren, M; Koren, G (Feb 2013). "Neonatal outcomes after gestational exposure to nitrofurantoin.". Obstetrics and gynecology 121 (2 Pt 1): 306–13. PMID 23344280.
- Crider, KS; Cleves, MA; Reefhuis, J; Berry, RJ; Hobbs, CA; Hu, DJ (Nov 2009). "Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.". Archives of pediatrics & adolescent medicine 163 (11): 978–85. doi:10.1001/archpediatrics.2009.188. PMID 19884587.
- Ben David, S; Einarson, T; Ben David, Y; Nulman, I; Pastuszak, A; Koren, G (1995). "The safety of nitrofurantoin during the first trimester of pregnancy: meta-analysis.". Fundamental & clinical pharmacology 9 (5): 503–7. doi:10.1111/j.1472-8206.1995.tb00525.x. PMID 8617414.
- Gardner, JS; Guyard-Boileau, B; Alderman, BW; Fernbach, SK; Greene, C; Mangione, EJ (Feb 1998). "Maternal exposure to prescription and non-prescription pharmaceuticals or drugs of abuse and risk of craniosynostosis.". International Journal of Epidemiology 27 (1): 64–7. doi:10.1093/ije/27.1.64. PMID 9563695.
- American College of Obstetricians and Gynecologists Committee on Obstetric Practice (Jun 2011). "ACOG Committee Opinion No. 494: Sulfonamides, nitrofurantoin, and risk of birth defects.". Obstetrics and gynecology 117 (6): 1484–5. doi:10.1097/AOG.0b013e3182238c57. PMID 21606771.
- Antibiot. Chemother. 1978, 25, 233–252
- McCalla DR, Kaiser C, Green MHL (1978). "Genetics of nitrofurazone resistance in Escherichia coli". J Bacteriol 133: 10–16.
- Bains A, Buna D, Hoag NA (2009). "A retrospective review assessing the efficacy and safety of nitrofurantoin in renal impairment". Canadian Pharmacists Journal 142 (5): 248–252. doi:10.3821/1913-701X-142.5.248.
- Tu Y, McCalla DR (1975). "Effect of activated nitrofurans on DNA,". Biochem Biophys Acta 402: 142–49.
- Williams, EM; Triller, DM (May 2006). "Recurrent acute nitrofurantoin-induced pulmonary toxicity.". Pharmacotherapy 26 (5): 713–8. doi:10.1592/phco.26.5.713. PMID 16718946.
- Goemaere, Natascha NT; Grijm, Karin; van Hal, Peter; den Bakker, Michael A (2008). "Nitrofurantoin-induced pulmonary fibrosis: a case report". Journal of Medical Case Reports 2 (1): 169. doi:10.1186/1752-1947-2-169. PMC 2408600. PMID 18495029. Retrieved 21 April 2014.
- Amit, G; Cohen, P; Ackerman, Z (Mar 2002). "Nitrofurantoin-induced chronic active hepatitis.". The Israel Medical Association journal : IMAJ 4 (3): 184–6. PMID 11908259.
- Tan, IL; Polydefkis, MJ; Ebenezer, GJ; Hauer, P; McArthur, JC (Feb 2012). "Peripheral nerve toxic effects of nitrofurantoin.". Archives of neurology 69 (2): 265–8. doi:10.1001/archneurol.2011.1120. PMID 22332195.
- Oplinger, M; Andrews, CO (Jan 2013). "Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence.". The Annals of pharmacotherapy 47 (1): 106–11. doi:10.1345/aph.1R352. PMID 23341159.
- American Geriatrics Society 2012 Beers Criteria Update Expert Panel (Apr 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.". Journal of the American Geriatrics Society 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677. PMID 22376048. Retrieved 21 April 2014.
- FAO: Nitrofuran study
- drugs.com for Macrodantin
- Meds-Help.com for nitrofurantoin side effects, interactions and information
- RxList for Macrobid (Nitrofurantoin)